Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis


The effects of ursodeoxycholic acid (UDCA, 450 mg daily) in patients with histologically proven chronic active hepatitis (CAH) have been evaluated in a randomized, double-blind, placebo-controlled study. Twenty-six patients with serum alanine aminotransferase (ALT) values at least twice the normal upper limit in two of three pre-treatment tests received… (More)
DOI: 10.1007/BF00315225


4 Figures and Tables